First-in-human phase I/II ICONIC trial of the ICOS agonist vopratelimab alone and with nivolumab: ICOS-high CD4 T-cell populations and predictors of response

Authors

Timothy A Yap, The University of Texas MD Anderson Cancer Center
Russell K Pachynski, Washington University School of Medicine in St. Louis
Haeseong Park, Washington University School of Medicine in St. Louis
Et al

Journal

Clinical cancer research : an official journal of the American Association for Cancer Research

Publication Date

9-1-2022

Volume

28

Issue

17

First Page

3695

Last Page

3708

Document Type

Open Access Publication

DOI

10.1158/1078-0432.CCR-21-4256

Rights and Permissions

Yap TA, Gainor JF, Callahan MK, Falchook GS, Pachynski RK, LoRusso P, Kummar S, Gibney GT, Burris HA, Tykodi SS, Rahma OE, Seiwert TY, Papadopoulos KP, Blum Murphy M, Park H, Hanson A, Hashambhoy-Ramsay Y, McGrath L, Hooper E, Xiao X, Cohen H, Fan M, Felitsky D, Hart C, McComb R, Brown K, Sepahi A, Jimenez J, Zhang W, Baeck J, Laken H, Murray R, Trehu E, Harvey CJ. First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response. Clin Cancer Res. 2022 Sep 1;28(17):3695-3708. doi: 10.1158/1078-0432.CCR-21-4256 This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.

Recommended Citation

Yap, Timothy A; Pachynski, Russell K; Park, Haeseong; and Et al, "First-in-human phase I/II ICONIC trial of the ICOS agonist vopratelimab alone and with nivolumab: ICOS-high CD4 T-cell populations and predictors of response." Clinical cancer research : an official journal of the American Association for Cancer Research. 28, 17. 3695 - 3708. (2022).
https://digitalcommons.wustl.edu/oa_4/414